BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36359850)

  • 1. Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.
    Burska AN; Ilyassova B; Dildabek A; Khamijan M; Begimbetova D; Molnár F; Sarbassov DD
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics.
    Wu X; Park M; Sarbassova DA; Ying H; Lee MG; Bhattacharya R; Ellis L; Peterson CB; Hung MC; Lin HK; Bersimbaev RI; Song MS; Sarbassov DD
    Int J Cancer; 2020 May; 146(10):2822-2828. PubMed ID: 31472018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Vitamin C Enantiomers Possess a Comparable Potency in the Induction of Oxidative Stress in Cancer Cells but Differ in Their Toxicity.
    Begimbetova D; Burska AN; Baltabekova A; Kussainova A; Kukanova A; Fazyl F; Ibragimova M; Manekenova K; Makishev A; Bersimbaev RI; Sarbassov DD
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth.
    Begimbetova D; Kukanova A; Fazyl F; Manekenova K; Omarov T; Burska AN; Khamijan M; Gulyayev A; Yermekbayeva B; Makishev A; Saliev T; Batyrbekov K; Aitbayev C; Spatayev Z; Sarbassov D
    Biomed Res Int; 2022; 2022():9426623. PubMed ID: 36619305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.
    Aguilera O; Muñoz-Sagastibelza M; Torrejón B; Borrero-Palacios A; Del Puerto-Nevado L; Martínez-Useros J; Rodriguez-Remirez M; Zazo S; García E; Fraga M; Rojo F; García-Foncillas J
    Oncotarget; 2016 Jul; 7(30):47954-47965. PubMed ID: 27323830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
    Yun J; Mullarky E; Lu C; Bosch KN; Kavalier A; Rivera K; Roper J; Chio II; Giannopoulou EG; Rago C; Muley A; Asara JM; Paik J; Elemento O; Chen Z; Pappin DJ; Dow LE; Papadopoulos N; Gross SS; Cantley LC
    Science; 2015 Dec; 350(6266):1391-6. PubMed ID: 26541605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic
    Cenigaonandia-Campillo A; Serna-Blasco R; Gómez-Ocabo L; Solanes-Casado S; Baños-Herraiz N; Puerto-Nevado LD; Cañas JA; Aceñero MJ; García-Foncillas J; Aguilera Ó
    Theranostics; 2021; 11(8):3595-3606. PubMed ID: 33664850
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis.
    Liu Y; Yue J; Ren Z; He M; Wang A; Xie J; Li T; Liu G; He X; Ge S; Yuan Y; Yang L
    Toxicol Appl Pharmacol; 2024 Jan; 482():116798. PubMed ID: 38160894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
    Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
    Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
    Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
    Biswas S; Zhao X; Mone AP; Mo X; Vargo M; Jarjoura D; Byrd JC; Muthusamy N
    Leuk Res; 2010 Jul; 34(7):925-31. PubMed ID: 20171736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species.
    Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A
    Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells.
    Hu M; Zhao Y; Cao Y; Tang Q; Feng Z; Ni J; Zhou X
    Cancer Sci; 2020 Oct; 111(10):3588-3599. PubMed ID: 32767829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas.
    Gao W; Xu Y; Chen T; Du Z; Liu X; Hu Z; Wei D; Gao C; Zhang W; Li Q
    PLoS Biol; 2019 Aug; 17(8):e3000425. PubMed ID: 31461438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
    Jung SA; Lee DH; Moon JH; Hong SW; Shin JS; Hwang IY; Shin YJ; Kim JH; Gong EY; Kim SM; Lee EY; Lee S; Kim JE; Kim KP; Hong YS; Lee JS; Jin DH; Kim T; Lee WJ
    Free Radic Biol Med; 2016 Jun; 95():200-8. PubMed ID: 27012422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
    Rathod LS; Dabhade PS; Mokale SN
    Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
    Huang L; Liu Z; Jiang H; Li L; Fu R
    J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.
    Yang H; Xiang S; Kazi A; Sebti SM
    J Biol Chem; 2020 Mar; 295(10):3055-3063. PubMed ID: 32001619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.